Additionally, some studies have explored the use of engineered immune cells that express a modified SIRPα receptor with higher binding affinity for CD47 or CD47-targeted CAR T-cell therapy to directly kill cancer cells and enhance the anti-tumor immune response [68,85]. This evidence concerns the gene CD47 and neoplasm.